Impact of Pneumosil Mass Campaigns on Reducing Pneumococcal Carriage in Niger: Promising Results from a Cluster-Randomised Trial
Valuable researchers have conducted a groundbreaking three-arm, open-label, cluster-randomised trial in Niger to evaluate the effectiveness of mass campaigns using full and fractional doses of the pneumococcal conjugate vaccine (Pneumosil, PCV10) in reducing nasopharyngeal pneumococcal carriage among children aged 1–9 years.









